J&J Says Experimental Prostate Cancer Drug Shrunk Tumors in Early-Stage Trial

Johnson & Johnson said its experimental once-daily oral prostate cancer drug caused tumors to disappear or shrink in an early-stage trial. J&J gained access to the drug through its $3.05 billion deal to buy Halda Therapeutics last year.